Design Therapeutics DSGN 深 沪
等待开盘 10-15 09:30:00 美东时间
9.73
-0.050
-0.51%
华盛通- 最 高9.99
- 今 开9.65
- 成交量 104.67万股
- 最 低 9.475
- 昨 收 9.78
- 总市值 6.09亿
- 52周最高 17.25
- 市盈率 静 --
- 换手率 1.67%
- 52周最低 5.73
- 委 比 11.11%
- 总股本 6258.17万
- 历史最高 50.50
- 量 比 2.17
- 振 幅 5.27%
- 历史最低 1.94
- 每 手 1
- 风险率 2.51%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Oppenheimer's fall 2026 SMID-cap ideas include four Strong Buy stocks
As investors look beyond the largest companies for potential opportunities, Oppenheimer Equity Research has updated its list of SMID-cap ideas for Fall 2026, highlighting a group of companies across t...
10-06 21:09
美股大行评级 | 潜在涨幅405.62%！Inventiva(IVA)获Truist Securities上调目标价至18美元，维持"买入"评级
今日重点评级关注：Truist Securities：维持Inventiva"买入"评级，目标价从13美元升至18美元；富瑞：维持Sagimet Biosciences"买入"评级，目标价从25美元升至26美元
10-05 16:26
Wells Fargo Initiates Coverage On Design Therapeutics with Overweight Rating, Announces Price Target of $26
Wells Fargo analyst Tianqi Hang initiates coverage on Design Therapeutics (NASDAQ:DSGN) with a Overweight rating and announces Price Target of $26.
10-02 22:23
Design Therapeutics to Participate in 2026 Cantor Fitzgerald Global Healthcare Conference
Design Therapeutics, a clinical-stage biotech company, announced that its management will participate in a fireside chat at the 2026 Cantor Fitzgerald Global Healthcare Conference on September 9, 2026, at 2:45 p.m. ET in New York. A live webcast will be available here and on the company’s website, www.designtx.com, and will be archived for at least 30 days. The company is developing GeneTAC® gene-targeted therapies to address degenerative genetic...
09-02 12:00
Marvell Technology, PayPal, Rubrik And Other Big Stocks Moving Lower In Friday’s Pre-Market Session
U.S. stock futures were mostly lower this morning, with the Nasdaq 100 futures falling around 0.3% on Friday. Shares of Marvell Technology Inc (NASDAQ:MRVL) fell sharply in pre-market trading following financial results for the second quarter. Marvell posted second-quarter revenue of $2.74 billion, ...
08-28 20:02
Design Therapeutics Q2 EPS $(0.32) Beats $(0.34) Estimate
Design Therapeutics (NASDAQ:DSGN) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate of $(0.34) by 5.88 percent. This is a 5.88 percent increase over losses of $(0.34) per share from the same period last year.
08-03 20:04
Design Therapeutics Provides RESTORE-FA Clinical Development Update and Reports Second Quarter 2026 Financial Results
Design Therapeutics reported Q2 2026 financial results and business updates. Positive four-week data from the RESTORE-FA trial for DT-216P2 in Friedreich ataxia supported modifications to the trial, with 12-week data expected in Q1 2027. Patient dosing began for DT-818 in myotonic dystrophy type 1. Cash and securities of $207.4 million provide strong financial runway. R&D expenses were $16.4 million, G&A expenses $5.8 million, and net loss $20.2 ...
08-03 12:00
Oppenheimer’s ‘best of the best’ momentum list: NVDA, LRCX and more
Nvidia (NVDA) and Lam Research (LRCX) are among the largest names on Oppenheimer’s latest “best of the best” momentum screen. Oppenheimer’s technical analysis team said the list provides technical col...
07-20 03:10
Design Therapeutics Starts Patient Dosing In Its Phase 1 Multiple-Ascending Dose Clinical Study Of DT-818 In Adults With Myotonic Dystrophy Type-1
Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced the initiation of patient dosing in its Phase 1 multiple-ascending dose (MAD) clinical trial evaluating DT-818 in adults with myotonic dys...
06-30 20:06
Design Therapeutics Announces Initiation of Patient Dosing in Phase 1 Multiple Ascending Dose Trial of DT-818 for Myotonic Dystrophy Type-1
Design Therapeutics has initiated a Phase 1 clinical trial for DT-818, a GeneTAC® molecule targeting myotonic dystrophy type-1 (DM1) by reducing transcription of the mutant DMPK allele. The trial aims to assess safety, tolerability, pharmacokinetics, and pharmacodynamics in adults with DM1. DT-818 has shown promise in preclinical studies, potentially addressing the underlying genetic cause of DM1. The company anticipates reporting data in 2027. D...
06-30 12:00
